Repository logo
 
Publication

Acute Kidney Injury and Electrolyte Imbalances Caused by Dapagliflozin Short-Term Use

2024Journal article Open access
Simple item page
dc.contributor.authorLopes, António Cabral
dc.contributor.authorLourenço, Olga
dc.contributor.authorMorgado, Sandra
dc.contributor.authorGaspar, Andreia
dc.contributor.authorFreire, Idalina
dc.contributor.authorEusébio, Inês
dc.contributor.authorRibeiro, João
dc.contributor.authorSilva, Mafalda
dc.contributor.authorMendes, Marta
dc.contributor.authorFonseca, Olimpia
dc.contributor.authorDuarte, Rute
dc.contributor.authorMorgado, Manuel
dc.date.accessioned2024-07-25T15:14:19Z
dc.date.available2024-07-25T15:14:19Z
dc.date.issued2024
dc.descriptionThis study was performed in line with the principles of the Declaration of Helsinki. Ethics approval was obtained from the Ethics Committees of the Local Health Unit of Guarda (SFTSS-REQ-22021) and the University Hospital Center of Cova da Beira (35/2023).pt_PT
dc.description.abstractDapagliflozin, a sodium–glucose cotransporter 2 inhibitor (SGLT2i), has shown demonstrated benefits for renal and cardiovascular outcomes in large clinical trials. However, short-term concerns regarding its impact on renal function and electrolyte balance exist. This study aimed to evaluate the short-term effects of dapagliflozin on renal function and electrolyte balance in patients newly prescribed the medication. A retrospective analysis of 246 patients who initiated dapagliflozin therapy was conducted. Serum creatinine, sodium, and potassium levels were measured at baseline (before dapagliflozin) and 5–8 days after initiation (endpoint). A Wilcoxon signed-rank test, Pearson’s chi-square test, and Fischer’s exact test were used for the data analysis. Glycemia and sodium levels were significantly higher at the baseline compared to the endpoint (p < 0.001). Conversely, creatinine and potassium levels were significantly higher at the endpoint than at the baseline (p < 0.001). The prevalence of hyponatremia and hyperkalemia were increased at the endpoint (17.5% vs. 10.2% and 16.7% vs. 8.9%, respectively). Although not statistically significant, a trend towards increased hyponatremia with the co-administration of furosemide was observed (p = 0.089). No significant association was found between potassium-sparing medications (p > 0.05) and hyperkalemia, except for angiotensin receptor blockers (p = 0.017). The combination of dapagliflozin and furosemide significantly increased the risk of acute kidney injury (AKI) at the endpoint (p = 0.006). Age, gender, andchronic kidney disease status did not significantly influence the occurrence of AKI, hyponatremia, or hyperkalemia (p > 0.05). These findings emphasize the importance of the close monitoring of renal function and electrolyte balance, particularly in the early stages of dapagliflozin therapy, especially in patients receiving diuretics or renin–angiotensin–aldosterone system inhibitors.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationLopes AC, Lourenço O, Morgado S, Gaspar A, Freire I, Eusébio I, Ribeiro J, Silva M, Mendes M, Fonseca O, Duarte R, Morgado M. Acute Kidney Injury and Electrolyte Imbalances Caused by Dapagliflozin Short-Term Use. Pharmaceuticals (Basel). 2024 Mar 26;17(4):420. doi: 10.3390/ph17040420. PMID: 38675382; PMCID: PMC11053518.pt_PT
dc.identifier.doi10.3390/ph17040420pt_PT
dc.identifier.urihttp://hdl.handle.net/10400.6/14455
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.relationHealth Sciences Research Centre
dc.relationHealth Sciences Research Centre
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectDapagliflozinpt_PT
dc.subjectElectrolyte balancept_PT
dc.subjectRenal functionpt_PT
dc.subjectType 2 diabetes mellitus - T2DMpt_PT
dc.titleAcute Kidney Injury and Electrolyte Imbalances Caused by Dapagliflozin Short-Term Usept_PT
dc.typejournal article
dspace.entity.typePublication
oaire.awardTitleHealth Sciences Research Centre
oaire.awardTitleHealth Sciences Research Centre
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDB%2F00709%2F2020/PT
oaire.awardURIinfo:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UIDP%2F00709%2F2020/PT
oaire.citation.issue4pt_PT
oaire.citation.startPage420pt_PT
oaire.citation.titlePharmaceuticalspt_PT
oaire.citation.volume17pt_PT
oaire.fundingStream6817 - DCRRNI ID
oaire.fundingStream6817 - DCRRNI ID
person.familyNameLourenço
person.familyNameMorgado
person.familyNameGaspar
person.familyNameEusébio
person.familyNameRibeiro
person.familyNameSilva
person.familyNameMendes
person.familyNamefonseca
person.familyNameDuarte
person.familyNameMorgado
person.givenNameOlga Maria Marques
person.givenNameSandra
person.givenNameAndreia
person.givenNameInês
person.givenNameJoão António Martins
person.givenNameMafalda
person.givenNameMarta
person.givenNameOlimpia
person.givenNameRute
person.givenNameManuel
person.identifier.ciencia-id6618-1C4C-D1B7
person.identifier.ciencia-idE61D-AB93-C4D4
person.identifier.ciencia-idFB1C-C8CF-C5D0
person.identifier.orcid0000-0002-8401-5976
person.identifier.orcid0000-0001-7072-5312
person.identifier.orcid0000-0001-8467-0578
person.identifier.orcid0000-0003-3418-6053
person.identifier.orcid0000-0002-7658-4837
person.identifier.orcid0000-0001-8395-6654
person.identifier.orcid0000-0002-8931-0456
person.identifier.orcid0009-0009-0473-5374
person.identifier.orcid0000-0002-5356-4366
person.identifier.orcid0000-0003-1663-0456
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.identifierhttp://doi.org/10.13039/501100001871
project.funder.nameFundação para a Ciência e a Tecnologia
project.funder.nameFundação para a Ciência e a Tecnologia
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublicationc890c74a-abc1-4910-aa70-f0da7b4ad902
relation.isAuthorOfPublication9c610080-3c57-4a48-9ece-15cc4261004a
relation.isAuthorOfPublication37eee3e2-6ae8-4472-9ef3-53397c250268
relation.isAuthorOfPublicationa7f383d9-4e10-4f10-8dba-c29fe25e95f5
relation.isAuthorOfPublicationfc981f6d-b5ca-4afe-a3be-b6d1682fa5c1
relation.isAuthorOfPublicatione630130e-868e-4681-835b-29fea9b7784d
relation.isAuthorOfPublicationa8b18ac3-46bd-4cb7-a65e-af39bdd38af6
relation.isAuthorOfPublicationa1ece1df-d2bd-4b5a-9809-209db51830e6
relation.isAuthorOfPublication405e24e9-3a20-46e8-8bac-5bf789d30a05
relation.isAuthorOfPublication2ebc82c8-f65a-4e3b-9bc9-6ad73ca46ca5
relation.isAuthorOfPublication.latestForDiscovery9c610080-3c57-4a48-9ece-15cc4261004a
relation.isProjectOfPublicationc7cee677-067c-47b2-ab19-b2dd5b0fda9d
relation.isProjectOfPublicationa4dfaeb8-2685-4a99-ba26-acc4e4a3d7c5
relation.isProjectOfPublication.latestForDiscoveryc7cee677-067c-47b2-ab19-b2dd5b0fda9d

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
2024_Lopes AC_Pharmaceuticals.pdf
Size:
461.14 KB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ICI - CICS | Documentos por Auto-Depósito
FCS - DCM | Documentos por Auto-Depósito